GlaxoSmithKline faces more Avandia fallout

Matthew Arnold,Marc Iskowitz

June 05 2007

GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.

Your Name: *

Your Email Address: *

Recipient(s) Email Address: *

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Subject:*

Your message:

Send Me A Copy

The e-mail address(es) that you supply to use this service will only be used to send the requested article.